Techorizon, a technology company based in Verona, Italy, with North American offices in Cambridge, Mass., has launched FeRMI, an electronic application for the conduct of clinical trial feasibility studies. Techorizon also launched a new web site.
Named after the length scale used in nuclear physics in recognition of the detailed data collected, FeRMI creates an entirely integrated, electronic approach to the conduct of feasibility studies and promotes faster, more effective study planning. Each step of the process is managed electronically, with data collection from sites completed via highly customizable online surveys which include real-time error checks. The investigator database module speeds selection of potential sites and tracks previous contacts and historical study performance. A real-time reporting module allows users to track trends emerging from the feasibility study whilst in progress, and ultimately to make better decisions about site selection.
“FeRMI revolutionizes clinical project planning by allowing our clients to conduct faster, more detailed, more accurate feasibility studies,” said Silvio Severini, managing director of Techorizon. “FeRMI adds to our Th-eClinical suite and is entirely unique, the first technology application to provide an end-to-end solution for the conduct of feasibility studies.”
Launched in 2009 as a separate company, Techorizon previously had provided technology services exclusively to Cromsource, an international CRO.